With Saturday quickly approaching and a celebration of “420” expected to make certain penny stocks rain in gains, Nuvilex, Inc. (NVLX) is hoping to be able to also capitalize on the smoke-screen created. Having nothing to do with the actual sale of marijuana or any other products having closed up shop on their more generally accepted products like Cinnergen and Talsyn, NVLX stock is still looking to sell the sizzle. Seeing as how it took off since announcing the new direction on February 11, perhaps these next two days could offer a chance to see what a dime looks like if even for just a second or two.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
NVLX Stock Quote
Market Cap: 31.50M
Last: 0.0685 ▼ -0.0029 (-4.06%)
Dollar Volume: $31,211
Issued and Outstanding: 459,782,825
1st Resistance Point: 0.0704
1st Support Level: 0.0675
2nd Support Level: 0.0666
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
Business has been relatively consistent for Nuvilex leading up to their entry into the Medical Marijuana sector by creating a wholly-owned subsidiary to conduct research on the gorgeous green creation from Mother Nature. Sales for the 3 months ended January 31, 2013 were non-existent compared to $20,271 during the same period in 2012. Even worse, the sales booked during the 9 months ended were just $12,160 compared to $59,877 for the same period the year prior.
Nuvilex’s President, CEO and Interim CFO, Robert F. Ryan, M.S., Ph.D., made it clear that the drop in incoming cash flow from product sales was due primarily to the decision by management to cease the spending of critical funds to maintain product sales below their actual cost. What a no-brainer of a decision.
What has been consistent has been Nuvilex’s stock dilution, 59.16 million shares issued during fiscal 2011 and another 41.65 million shares of NVLX stock issued between May 1, 2012 and January 31, 2013. How else can the struggling to stay afloat wannabe biotech player keep up with the Joneses and pay off their nearly $4 million in debt?
What is gonna help to keep NVLX stock at its current range is the continued news flow regarding medical marijuana and possible human clinical trials through partnerships and joint ventures. Cheech and Chong pretty much covered the subject matter to the fullest extent in their nearly 10 motion pictures made popular in the late 70′s and early 80′s on the matter.
With a ton of shares both issued and available to be issued, the move towards the marijuana sector and inclusion in generalized matter about marijuana which includes Nuvilex’s name is about the only thing the Company has going for it at present. Can they research Cannabis sativa effectively and have it make a positive impact on their bottom line numbers in the coming decade? Much of the world population has been attempting the same and very few have turned it into a money making venture.
About NVLX Stock
Nuvilex, Inc., a biotechnology and life technology company, is now also focused on the booming search and development market for the treatment of diseases using compounds derived from the Cannabis sativa plant through their recently created wholly-owned subsidiary, Medical Marijuana Sciences, Inc.
Last 5 Trading Sessions:
NVLX is worth a look pre-market since almost every other penny stock in its price range has either shat the bed in recent days (BOPT, EXLA, PUNL, HIDC, TTIN), or just doesn’t have the juice to create awareness. Psycho has a sub-penny alert going out which will “gap and trap” the early traders which might make NVLX an attractive lipsticked pig of a trade prior to 4/20. At the end of the day though, if Medical Marijuana (MJNA) ain’t running, every other player in the sector is just having a mini-sprint before pulling up with a cramp.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)